Schedule 13D ownership disclosure
NEWLINK GENETICS CORP
Security class unavailable · CUSIP: 651511107
Event date: 2017-10-06
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 7,857,732
- Percent of class
- 21.2000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001512112-17-000003
- Form type
- SC 13D
- Filer
- LUMOS PHARMA, INC.
- CIK
- CIK 1126234
- Filed
- Oct 06, 2017
- Reporting period
- Oct 06, 2017
- Description
- Schedule 13D beneficial ownership